Adaptive (ADPT) news

Adaptive Biotechnologies Corporation: TD Cowen raises target price to $32 from $28

TD Cowen has revised its price target for Adaptive Biotechnologies Corporation (ADPT), raising it to $32 from $28, reflecting a positive outlook on the company’s growth prospects. As of October 12, 2026, the stock closed at $25.57, representing a decline of 3.47% from the previous session. The…

AdvancedAdvt Ltd: Hy trading remains in line with management expectations

AdvancedAdvt Ltd (ADVT) continues to report trading performance consistent with management expectations, with no significant deviations noted in recent operations. The company recently completed a share buyback of 243,453 shares , reflecting its ongoing commitment to managing capital structure and…

Adaptive Biotechnologies Corp: TD Cowen raises target price to $28 from $25

ADPT 2Q adj. EBITDA loss $0.73M, est. loss $3.75M

Adaptive Biotechnologies (Nasdaq: ADPT) reported a narrower-than-expected adjusted EBITDA loss of $0.73 million for the second quarter of 2024, significantly below the estimated loss of $3.75 million. The company’s MRD (Minimal Residual Disease) segment, which accounts for the majority of its…

Adapthealth Corp: Jefferies raises to buy from hold; raises target price to $13 from $11

Jefferies has upgraded its rating for Adapthealth Corp (ADPT) from "hold" to "buy," reflecting a more favorable outlook on the company’s prospects. Alongside the rating change, the firm also raised its price target to $13 from $11. The adjustment follows a recent analysis of Adapthealth’s business…